Printer Friendly

TELIOS ANNOUNCES FIRST QUARTER 1992 RESULTS

 TELIOS ANNOUNCES FIRST QUARTER 1992 RESULTS
 SAN DIEGO, April 23 /PRNewswire/ -- Telios Pharmaceuticals Inc.


("Telios" or the "Company") (NASDAQ-NMS: TLIO) announced today financial results for its first quarter ended March 31, 1992. Revenues for the quarter were $527,000, a decrease from $787,000 for the same period last year. The Company incurred a net loss of $4,308,000 or $.25 per share, compared to $1,621,000 or $.10 per share for the same period in 1991. This increase was primarily the result of increased clinical, research and development activities.
 Telios is developing a new class of therapeutic products based upon research into the role of the extracellular matrix. The Company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic disease, cardiovascular disease and osteoporosis. The Company currently is in clinical trials with two novel peptide-based products, Telio-Derm(TM), a treatment designed to accelerate healing of severe and chronic dermal wounds, and OcuNex(TM), an ophthalmic wound healing product.
 The common stock of Telios is traded on the NASDAQ National Market System under the symbol TLIO.
 -0- 4/23/92
 /CONTACT: David Duncan Jr., VP-Finance, or Richard A. Kaufman, VP, Secretary and General Counsel, of Telios Pharmaceuticals, 619-622-2615/
 (TLIO) CO: Telios Pharmaceuticals Inc. ST: California IN: MTC SU: ERN


JL-KJ -- SD009 -- 2201 04/23/92 18:11 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 23, 1992
Words:231
Previous Article:SIERRA CLUB MISLEADS PUBLIC MOBIL SAYS
Next Article:FLORIDA REGIONAL STOCK REPORT FOR FRIDAY, MAY 22


Related Articles
TELIOS INITIATES CLINICAL TRIALS FOR ADDITIONAL DERMAL WOUND HEALING APPLICATIONS; INTERIM ANALYSIS REVEALS ADEQUATE SAMPLE SIZE
TELIOS ANNOUNCES SECOND QUARTER 1992 RESULTS
TELIOS ANNOUNCES THIRD QUARTER 1992 RESULTS
TELIOS ANNOUNCES FOURTH QUARTER 1992 RESULTS
TELIOS ANNOUNCES FIRST QUARTER 1993 RESULTS
TELIOS ANNOUNCES SECOND QUARTER 1993 RESULTS
TELIOS ANNOUNCES THIRD QUARTER 1993 RESULTS
TELIOS ANNOUNCES 1993 RESULTS
TELIOS ANNOUNCES FIRST QUARTER 1994 RESULTS
TELIOS ANNOUNCES FIRST QUARTER 1995 RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters